{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T20:18:57Z","timestamp":1770063537811,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012359","name":"Promotion and Mutual Aid Corporation for Private Schools of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.bcp.2007.11.011","type":"journal-article","created":{"date-parts":[[2007,12,4]],"date-time":"2007-12-04T09:17:50Z","timestamp":1196759870000},"page":"1322-1330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure"],"prefix":"10.1016","volume":"75","author":[{"given":"Punniyakoti T.","family":"Veeraveedu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh S.","family":"Palaniyandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken\u2019ichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifusa","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2007.11.011_bib1","series-title":"Davidson's principles and practice of medicine","author":"Haslet","year":"1999"},{"key":"10.1016\/j.bcp.2007.11.011_bib2","first-page":"23","article-title":"Body fluid volume regulation in health and disease","volume":"39","author":"Abraham","year":"1994","journal-title":"Adv Intern Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib3","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib4","doi-asserted-by":"crossref","first-page":"F1115","DOI":"10.1152\/ajprenal.00337.2002","article-title":"Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure","volume":"284","author":"Chen","year":"2003","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib5","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1161\/hc1102.105264","article-title":"BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy","volume":"105","author":"Gottlieb","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2007.11.011_bib6","first-page":"169","article-title":"Tubuloglomerular feedback and the control of glomerular filtration rate","volume":"18","author":"Vallon","year":"2003","journal-title":"News Physiol Sci"},{"key":"10.1016\/j.bcp.2007.11.011_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0735-1097(99)00608-7","article-title":"The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction","volume":"35","author":"Dries","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib8","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","article-title":"Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction","volume":"100","author":"Cooper","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2007.11.011_bib9","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","article-title":"Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure","volume":"73","author":"Lee","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2007.11.011_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.bcp.2007.11.011_bib12","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/01.HYP.26.5.828","article-title":"Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism","volume":"26","author":"Burrell","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2007.11.011_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.23.6.737","article-title":"Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat","volume":"23","author":"Burrell","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.bcp.2007.11.011_bib14","first-page":"H2245","article-title":"Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs","volume":"267","author":"Naitoh","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib15","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.bcp.2007.07.027","article-title":"Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure","volume":"74","author":"Veeraveedu","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2007.11.011_bib16","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2007.11.011_bib17","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Tolvaptan investigators. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.bcp.2007.11.011_bib18","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bcp.2007.11.011_bib20","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.bcp.2007.11.011_bib21","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","article-title":"Effects of the V2-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2007.11.011_bib22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1038\/sj.bjp.0703450","article-title":"Low dose carvedilol inhibits progression of heart failure in rats with dilated cardiomyopathy","volume":"130","author":"Watanabe","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.bcp.2007.11.011_bib23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0090-1229(90)90039-S","article-title":"A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction","volume":"57","author":"Kodama","year":"1990","journal-title":"Clin Immunol Immunopathol"},{"key":"10.1016\/j.bcp.2007.11.011_bib24","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1210\/en.2004-1590","article-title":"Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia","volume":"146","author":"Miyazaki","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.bcp.2007.11.011_bib25","first-page":"R249","article-title":"Plasma vasopressin response to peripheral administration of angiotensin in conscious rats","volume":"248","author":"Yamaguchi","year":"1985","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib26","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/clinchem\/40.7.1220","article-title":"Application of the clearance concept to hyponatremic and hypernatremic disorders: a phenomenological analysis","volume":"40","author":"Shoker","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.bcp.2007.11.011_bib27","first-page":"16","article-title":"Effective water clearance and tonicity balance: the excretion of water revisited","volume":"20","author":"Mallie","year":"1997","journal-title":"Clin Invest Med"},{"issue":"Suppl 7","key":"10.1016\/j.bcp.2007.11.011_bib28","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1097\/00005344-198600087-00008","article-title":"Discovery and therapeutic utility of vasopressin antagonists in rats","volume":"8","author":"Kinter","year":"1986","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.bcp.2007.11.011_bib29","first-page":"F159","article-title":"Sites of hormone action in the mammalian nephron","volume":"240","author":"Morel","year":"1981","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-103-1-1","article-title":"Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis","volume":"103","author":"Francis","year":"1985","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib31","first-page":"273","article-title":"Diuretics as initial and sole treatment in chronic cardiac failure","volume":"2","author":"Anand","year":"1991","journal-title":"Cardioscience"},{"key":"10.1016\/j.bcp.2007.11.011_bib32","first-page":"F486","article-title":"Renin release from isolated juxtaglomerular apparatus depends on macula densa chloride transport","volume":"260","author":"Lorenz","year":"1991","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3181\/00379727-150-38982","article-title":"Furosemide induced release of prostaglandin E to increase renal blood flow","volume":"150","author":"Williamson","year":"1975","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0090-6980(77)90265-9","article-title":"Effect of furosemide on urinary excretion of prostaglandin E in normal volunteers and patients with essential hypertension","volume":"14","author":"Abe","year":"1977","journal-title":"Prostaglandins"},{"key":"10.1016\/j.bcp.2007.11.011_bib35","first-page":"1123","article-title":"Prostaglandin-mediated renin release from renal cortical slices","volume":"7","author":"Whorton","year":"1980","journal-title":"Adv Prostagl Thromb Res"},{"key":"10.1016\/j.bcp.2007.11.011_bib36","first-page":"F276","article-title":"Renin release selectively stimulated by prostaglandin I2 in isolated rat glomeruli","volume":"243","author":"Beierwaltes","year":"1982","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib37","first-page":"F929","article-title":"Role of prostaglandin in norepinephrine and renin release in canine kidney","volume":"253","author":"Hayashi","year":"1987","journal-title":"Am J Physiol"},{"key":"10.1016\/j.bcp.2007.11.011_bib38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0022-3565(25)30703-2","article-title":"Natriuretic effect of furosemide after inhibition of prostaglandin synthetase","volume":"199","author":"Bailie","year":"1976","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.bcp.2007.11.011_bib39","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib41","first-page":"209","article-title":"Micropuncture study of the effect of furosemide on proximal and distal tubules of the rat nephron","volume":"18","author":"Romano","year":"1995","journal-title":"Ren Physiol Biochem"},{"key":"10.1016\/j.bcp.2007.11.011_bib42","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1748-1716.1995.tb09952.x","article-title":"Effect of furosemide on local and zonal glomerular filtration rate in the rat kidney","volume":"155","author":"Tenstad","year":"1995","journal-title":"Acta Physiol Scand"},{"key":"10.1016\/j.bcp.2007.11.011_bib43","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2003.06.005","article-title":"Vasopressin receptor antagonists in heart failure","volume":"3","author":"Thibonnier","year":"2003","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.bcp.2007.11.011_bib44","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/0002-9343(67)90091-5","article-title":"Metabolism of antidiuretic hormones","volume":"42","author":"Lauson","year":"1967","journal-title":"Am J Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib45","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2007.11.011_bib46","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295207007666?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295207007666?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T12:49:08Z","timestamp":1757767748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295207007666"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0006295207007666"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2007.11.011","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2007.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}